A study published in the International Journal of Dermatology suggests that oral roflumilast is a safe and effective therapy ...

SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar ...

Under in-vitro test conditions, dentures fabricated from this proprietary 3D-printing resin have exhibited a >99.9% reduction in the most common bacteria and fungi known to cause biofilm and ...

For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab ...

Researchers from the Interdisciplinary Research Laboratory (LII) of ENES Leon, UNAM, have created an approach for ...

Nagalo is the first UAMS researcher to receive the New Innovator Award from the NIH. Previous award recipients have come from ...

Specifically, a virus called vesicular stomatitis has shown promise in treating tough-to-treat cancers like pancreatic ductal adenocarcinoma, but safety concerns have limited its use.

A new directive issued by the Minister of Municipalities Affairs and Agriculture, Wael Al Mubarak, has made it clear: failing ...

The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant ...

Itovebi is supplied as a tablet in 2 dosage strengths: 3 mg and 9 mg. Patients should be selected for treatment based on the presence of 1 or more PIK3CA mutations in plasma specimens. The FDA has ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...

The FDA also approved the FoundationOne Liquid CDx assay to identify patients who qualify for the newly approved treatment.